2001603
print

Neisseria meningitidis Tetravalent Antibodies (Serogroups A, C, W-135 and Y), IgG

NMENING
Example Reports
Protected
Unprotected

Ordering Recommendation

Use to assess immunocompetence following Neisseria meningitidis vaccination. To assess suspected immunodeficiency, use pre- and postvaccination serology. Do not use for diagnosis of infection or serotyping.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Serum separator tube. Postimmunization specimen should be drawn 30 days after immunization and, if shipped separately, must be received within 60 days of preimmunization specimen.

Specimen Preparation

Separate serum from cells ASAP or within 2 hours of collection. Transfer 1.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.25 mL) MARK SPECIMENS CLEARLY AS PRE- OR POSTPNEUMOCOCCAL VACCINE SO SPECIMENS WILL BE SAVED AND TESTED SIMULTANEOUSLY.

Storage/Transport Temperature

Refrigerated. Pre- and postpneumococcal vaccine specimens can be submitted separately or together for testing.

Unacceptable Conditions

Plasma or other body fluids. Contaminated, hemolyzed or severely lipemic specimens.

Remarks
Stability

After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles).

Methodology

Quantitative Multiplex Bead Assay

Performed

Mon

Reported

1-8 days

Reference Interval

N. meningitidis A, C, W-135 and Y, IgG:
0.9 µg/mL or less: Antibody concentration not protective.
1.0-2.0 µg/mL: Equivocal.
2.1 µg/mL or greater: Antibody to Neisseria meningitidis detected. Suggestive of protection.

Responder status is determined according to the ratio of the one month post-vaccination concentration to pre-vaccination concentration of IgG antibodies to N. meningitidis (Types A, C, Y, and W-135) as follows:

1. If the one month post-vaccination concentration is less than 3.0 µg/mL, the patient is considered to be a non-responder.
2. If the one month post-vaccination concentration is greater than or equal to 3.0 µg/mL, a patient with a ratio of greater than or equal to 4 is a good responder, a ratio of  2-4 is a weak responder, and a ratio of less than 2 is considered a non-responder

Interpretive Data

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

N/A

CPT Codes

86741 x4

Are you an ARUP Client? Click here for your pricing.

Components

Component Test Code* Component Chart Name LOINC
2001604 N.meningitidis Type A IgG 28546-0
2001605 N.meningitidis Type C IgG 28547-8
2001606 N.meningitidis Type Y IgG 60466-0
2001607 N.meningitidis Type W-135 IgG 60465-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Meningococcal IgG Vaccine Response
  • N. Meningitidis IgG Vaccine Response
  • Neisseria meningitidis
  • Vaccine Response
Neisseria meningitidis Tetravalent Antibodies (Serogroups A, C, W-135 and Y), IgG